Veracyte (NASDAQ:VCYT) is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.
The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules. In addition, Veracyte offers the Percepta Genomic Sequencing Classifier for patients with lung nodules, as well as the Envisia Genomic Classifier for patients with suspected interstitial lung disease. These tests leverage RNA sequencing and advanced bioinformatics to deliver clinically actionable results, enabling more precise risk stratification and management of patients.
Veracyte operates certified laboratories in South San Francisco and Europe, serving a broad network of endocrinologists, pulmonologists and pathologists across the United States, Canada and selected European markets. The company collaborates with healthcare organizations and specialty groups to integrate its tests into diagnostic workflows, supporting evidence-based medicine and cost-effective care. Veracyte’s commercial operations are supported by a field sales force, partnerships with reference laboratories and direct engagement with key opinion leaders in oncology and pulmonary medicine.
Under the leadership of CEO Bonnie H. Anderson, Veracyte has pursued strategic growth initiatives, including the expansion of its test menu and development of new molecular classifiers. The company’s management team combines expertise in genomics, diagnostic development and commercial operations, positioning Veracyte to advance its pipeline and capitalize on emerging opportunities in precision diagnostics. By continuing to innovate in genomic science and build strategic partnerships, Veracyte aims to expand access to its tests and further enhance diagnostic accuracy worldwide.
